BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA

FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, too

Endpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinic

FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract Pharma

Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times

Endpoints NewsParabilis Medicines charts $413M IPO to back peptide pipeline

FierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC

PharmaVoiceHouse bill aims to crack down on China biotech deals

PharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problems

FierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’